BRUKINSA® (zanubrutinib) patient case review in 1L CLL with Dr Pinilla-Ibarz

Dr Javier Pinilla-Ibarz, head of the lymphoma section at the Moffitt Cancer Center in Tampa, Florida, presents a case of a patient with CLL with a del(17p)/TP53 mutation in 1L, and discusses the efficacy benefits of BRUKINSA in these patients. BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Serious adverse reactions, including fatal events, have occurred with BRUKINSA, including hemorrhage, infections, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity (including drug-induced liver injury). In the pooled safety population (N=1729), the most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA were neutrophil count decreased (51%), platelet count decreased (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%). Please see full Prescribing Information: https://brukinsahcp.com/wp-content/up... This content is intended for US Healthcare Professionals only. Learn more at: https://brukinsahcp.com/cll/